Hyung Sub Park
Seoul National University · 医学
研究室紹介
Professor Hyung Sub Park's research lab focuses on translational biomedical research with an emphasis on metabolic disorders, vascular diseases, and microcirculatory dysfunction. The lab investigates the therapeutic potential of metabolites like β-aminoisobutyric acid (BAIBA) in obesity-related metabolic diseases and explores innovative models for lymphedema and venous insufficiency. Additionally, the lab examines diagnostic and therapeutic applications of laser Doppler imaging in diabetes-related microvascular complications and evaluates clinical outcomes of endovenous ablation techniques.
Research Overview
Research Output Trend
Figures are computed from collected data and may differ slightly.
Selected Papers
15BACKGROUND: β-aminoisobutyric acid (BAIBA) is produced in skeletal muscle during exercise and has beneficial effects on obesity-related metabolic disorders such as diabetes and non-alcoholic fatty liver disease. Thus, it is supposed to prevent high fat diet (HFD)-induced inflammation and insulin resistance in adipose tissue though anti-inflammatory effects in obesity. Previous reports have also demonstrated strong anti-inflammatory effects of BAIBA. METHODS: We used BAIBA treated fully different
Secondary lymphedema is an intractable disease mainly caused by damage of the lymphatic system during surgery, yet studies are limited by the lack of suitable animal models. The purpose of this study was to create an improved model of secondary lymphedema in the hindlimbs of rodents with sustained effects and able to mimic human lymphedema. This was achieved by combining previously reported surgical methods and radiation to induce chronic lymphedema. Despite more radical surgical destruction of
RFA is an effective and safe treatment modality for incompetent SSV. Peak reflux velocity can be a risk factor for recanalization. Length of RFA segment in SSV does not affect recanalization and postablation sural neuritis.
OBJECTIVE: We evaluated whether LD can detect alterations in skin microcirculatory flow in type II diabetic neuropathy patients and determined which parameters were most predictive. METHODS: A prospective analysis was performed for three groups with presumed varying degrees of microvascular dysfunction: diabetics with neuropathy (DMN, n = 20), diabetics without microangiopathic complications (DM, n = 20), and healthy controls (n = 16). LD was performed under strictly controlled protocols with pr
Overall QoL and recurrence rates were similar between the two modalities. The benefits of RFA do not seem to be enough to overcome the higher costs of HS in Korea.
Coronavirus disease 2019 (COVID-19) has had a major impact on global communities and healthcare. Paxlovid (nirmatrelvir/ritonavir) is an oral drug for the treatment of COVID-19 that has been approved by the U.S. Food and Drug Administration. In Korea, Paxlovid is the first-line drug for patients who are >60 years old or using immunosuppressants, or those who are >40 years old with chronic diseases such as obesity, diabetes, chronic kidney disease, or hypertension. One caveat of Paxlovid treatmen
The pathogenic mechanism of nicotine, a major product of smoking, on vascular endothelial cells is not well defined yet. The purpose of this study was to determine whether chronic exposure to nicotine alters angiogenic activity in human umbilical vein endothelial cells and to identify a potential role for endothelial nitric oxide synthase (eNOS) expression. Our study demonstrated that acute nicotine treatment enhanced nitric oxide release, eNOS activation, and proangiogenic activity. However, ch
The use of nanomaterials for biomedical applications has become a promising field in regenerative medicine. Self-assembling peptides (SAPs) have been proposed as a good candidate because they are able to self-assemble into stable hydrogels and interact with cells or molecules when combined together. This in turn can lead to the improved survival or action of cells or molecules to obtain the desired effects. In this study, we investigated whether the combination of mesenchymal stem cells (MSCs) w
Muscle-derived stem cells (MDSCs) are known to promote angiogenesis, but have never been studied in vascular diseases. We differentiated MDSCs into endothelial lineage cells in vitro by stimulation with shear stress and vascular endothelial growth factor. Such differentiated MDSCs (diff-MDSC) showed strong angiogenic potential in vitro. When tested in ischemic hindlimbs of mice, diff-MDSCs increased perfusion and decreased necrosis of the ischemic limbs, by promoting new vessel formation and by